Abnova — Interim / Quarterly Report 2020

Sep 22, 2020

==> picture [794 x 119] intentionally omitted <==

==> picture [794 x 121] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

1

Safe Harbor Notice

The following pages contain projections & estimates of financial information as well as market and product developments for future periods. These projections & estimates are based on information currently available which we believe to be reliable, but they involve risks & uncertainties. Our actual results of operations & financial condition may differ significantly from those contained in the projections & estimates. The projections & estimates should not be interpreted as legally binding commitments, but rather as flexible information subject to change occasionally.

2

Agenda

✓ Company Profile

• Q2&H1-2020 Financial Results

✓ Abnova COVID-19 Products

✓ Q&A

==> picture [794 x 120] intentionally omitted <==

3

==> picture [794 x 119] intentionally omitted <==

==> picture [794 x 121] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

I. ABNOVA COMPANY PROFILE

4

Abnova Company Profile

==> picture [452 x 227] intentionally omitted <==

==> picture [452 x 228] intentionally omitted <==

==> picture [273 x 363] intentionally omitted <==

5

Consolidated Income Statement Q2&H1 2020

									In NT$K
	Q2‘20	%	Q2‘19	%	H1‘20	%	H1‘19	%	H1 YOY
Net Revenue	103,319	100%	103,591	100.00%	203,229	100.00%	212,172	100.00%	(4.21%)
Cost of Revenue	(56,609)	(54.79%)	(59,721)	(57.7%)	(110,523)	(54.38%)	(125,624)	(59.2%)	(12.02%)
Gross Profit	46,710	45.21%	43,870	42.3%	92,706	45.62%	86,548	40.8%	7.12%
Operating Expense	(38,309)	(37.08%)	(45,306)	(43.7%)	(77,020)	(38.90%)	(90,616)	(42.7%)	(15.00%)
Operating Income	8,401	8.13%	(1,436)	(1.4%)	15,686	6.72%	(4,068)	(1.9%)	485.59%
Non Operating Income	(3,009)	(2.91%)	2,374	2.3%	(900)	(1.44%)	3,133	1.5%	(128.73%)
Income before Tax	5,392	5.22%	938	0.9%	14,786	6.28%	(935)	(0.4%)	1681.39%
Income after Tax	4,122	3.99%	2,503	2.4%	11,818	4.82%	634	0.3%	1764.04%
Basic EPS after Tax	0.07		0.04		0.2		0.01

6

Revenue Breakdown by Products

==> picture [794 x 359] intentionally omitted <==

----- Start of picture text -----

In NT$K
450,000 2020 Jan-Aug
400,000
101,562
350,000
300,000
64,473
61,959 21%
250,000
49,215 Antibody
200,000
36,224 50% Protein
150,000
Others
248,123
17%
100,000
COVID-19 related
146,651
50,000
12%
0
2019 2020 Jan-Aug
----- End of picture text -----

Antibody Protein Others COVID-19 related

7

==> picture [794 x 119] intentionally omitted <==

==> picture [794 x 121] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

8

==> picture [794 x 119] intentionally omitted <==

==> picture [794 x 121] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

II. ABNOVA COVID-19 PRODUCTS

9

COVID-19 Automated RNA Extraction

==> picture [794 x 121] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

10

COVID-19 Human IgM IgG Rapid Test

• Fast, convenient, reliable

New Utility: Finger Prick Blood Test

==> picture [794 x 410] intentionally omitted <==

----- Start of picture text -----

•
Results in 15 minutes
•
Easy to operate
•
Highly sensitive via visual inspection
CE IVD Approved
----- End of picture text -----

11

COVID-19 Human IgM IgG ELISA Kit DELUXE

COVID-19 Human ELISA Kit DELUXE is an IgM IgG indirect enzyme-linked immunoassay for qualitative determination of COVID-19 (SARS-CoV-2) human serum IgM and IgG.

==> picture [794 x 120] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

12

COVID-19 Viral Antigen Rapid Test (Pending)

==> picture [794 x 121] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

13

COVID-19 Viral Antigen ELISA Kits

Sandwich enzyme-linked immunosorbent assays for the quantitative measurement of COVID-19 viral or . spike antigen nucleocapsid antigen

COVID-19 Viral Antigen S ELISA Kit COVID-19 Viral Antigen N ELISA Kit

==> picture [794 x 120] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

14

COVID-19 Cell-Based Neutralization Antibody Assay

==> picture [76 x 75] intentionally omitted <==

Serum Pseudovirus Spike protein

==> picture [56 x 54] intentionally omitted <==

==> picture [794 x 278] intentionally omitted <==

----- Start of picture text -----

Pseudovirus infected and cells
expressed luciferase
Neutralized
----- End of picture text -----

Pseudovirus/Antibody

293T-ACE2 cell

Without luciferase expression

COVID-19 Therapeutic Antibody

(A) Antibody with Spike protein Flow cytometer analysis

==> picture [103 x 179] intentionally omitted <==

==> picture [105 x 120] intentionally omitted <==

----- Start of picture text -----

Antibody
Spike protein
----- End of picture text -----

(B) Antibody with Pseudovirus

==> picture [385 x 193] intentionally omitted <==

----- Start of picture text -----

Neutralized Non-neutralized
Mouse IgG
----- End of picture text -----

Luciferase activity assay

==> picture [794 x 120] intentionally omitted <==

One of three candidate antibodies has completed humanization.

COVID-19 Self-Amplifying mRNA Vaccine (Pending)

==> picture [694 x 153] intentionally omitted <==

==> picture [694 x 154] intentionally omitted <==

==> picture [694 x 153] intentionally omitted <==

17

==> picture [794 x 119] intentionally omitted <==

==> picture [794 x 121] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

==> picture [794 x 120] intentionally omitted <==

18